# About This Research Desk

> About Carolina Peptide — A Comparative Reading of the Tissue-Repair Literature — About Carolina Peptide: an independent literature digest on three Recovery & Tissue Repair research peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice.

**RECOVERY & TISSUE REPAIR RESEARCH / COLOPHON**

An independent, citation-anchored digest of the soft-tissue and connective-tissue repair literature. Not a vendor. Not a clinic. Not medical advice.

## What Carolina Peptide is

Carolina Peptide sets three research peptides side by side around one theme — **soft-tissue and connective-tissue repair**: GLOW (a three-peptide combination), KPV (a gut-focused anti-inflammatory tripeptide), and TB-500 (an actin-binding fragment of thymosin beta-4), with TB-500 leading. Each gets its own page; a comparison page lines them up across mechanism, depth of evidence, and regulatory standing; and one shared reference list gathers every citation used across the three.

The organizing discipline here is quantitative wherever the literature allows it: species and sample size, dose or dose-range, and effect size — a percentage, a hazard figure, an mg/kg — rather than adjectives. Where a finding rests on 40 human volunteers and where it rests on a single mouse-colitis model are two very different evidentiary positions, and this desk states which is which every time.

## How it is compiled

Two rules shape the pages. First, every factual claim carries a numbered citation — peer-reviewed, PubMed-indexed work with a DOI or PubMed link, collected on the [references page](/references) — and anything taken from a review rather than a primary study is marked that way. Second, a finding is reported at the strength it was actually measured, never the strength a marketing line would imply: a Phase 1 safety trial in 40 healthy volunteers is called exactly that, not stretched into an efficacy claim, and a blend like GLOW is described as having no blend-level trials at all, however well its separate ingredients are studied. Where the fragment-versus-full-protein question muddies a claim — a recurring problem across the TB-500 literature — the muddle is stated outright, not smoothed away.

## What it is not

None of this is a pharmacy, a clinic, or a storefront. Carolina Peptide neither sells nor sources nor brokers GLOW, KPV, TB-500, or their constituents, and holds no affiliate tie to any research-chemical supplier. It names no dose, schedule, or route for any person, and none of the three compounds is FDA-approved for human use. Two of them — TB-500 directly, GLOW by way of it — are barred from tested competition. Anyone with a personal medical question should bring it to a licensed clinician. Corrections to the record — a stale citation, a fresh trial — are welcome through the [contact page](/contact), though nothing here answers requests for medical advice.

---

A data-first ledger of tissue-repair peptide research — effect sizes and citations, not a clinic or a shop.